269.13MMarket Cap-9612P/E (TTM)
4.410High4.210Low105.83KVolume4.270Open4.370Pre Close454.03KTurnover0.41%Turnover RatioLossP/E (Static)63.77MShares6.35052wk High1.72P/B108.31MFloat Cap2.00052wk Low--Dividend TTM25.67MShs Float37.550Historical High--Div YieldTTM4.58%Amplitude2.000Historical Low4.290Avg Price1Lot Size
Zura Bio Stock Forum
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
NEWS
Zura Bio Raises $112.5M Through Private Placement Deal
NEWS
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
No comment yet